Cargando…
From selection hits to clinical leads: progress in aptamer discovery
Aptamers were discovered more than 25 years ago, yet only one has been approved by the US Food and Drug Administration to date. With some noteworthy advances in their chemical design and the enzymes we use to make them, aptamers and aptamer-based therapeutics have seen a resurgence in interest. New...
Autores principales: | Maier, Keith E, Levy, Matthew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822646/ https://www.ncbi.nlm.nih.gov/pubmed/27088106 http://dx.doi.org/10.1038/mtm.2016.14 |
Ejemplares similares
-
Robust Strategy
for Hit-to-Lead Discovery: NMR for
SAR
por: Larda, Sacha T., et al.
Publicado: (2023) -
Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects
por: Kruspe, Sven, et al.
Publicado: (2017) -
A comparative analysis of cell surface targeting aptamers
por: Kelly, Linsley, et al.
Publicado: (2021) -
The application of Aptamer in biomarker discovery
por: Li, Yongshu, et al.
Publicado: (2023) -
Combining independent protein and cellular SELEX with bioinformatic analysis may allow high affinity aptamer hit discovery
por: Ducrot, Coline, et al.
Publicado: (2023)